Agilent Technologies (A) 2025 Earnings Quality Report

Grade: C — Two Items Warrant Investigation

Framework: Schilit *Financial Shenanigans* + Beneish M-Score + forensic accounting principles

Data: SEC EDGAR 10-K (Filed 2025-12-22, fiscal year ended October 31, 2025) + Yahoo Finance

Auditor: PricewaterhouseCoopers LLP — Clean opinion (1 Critical Audit Matter)

One-line verdict: Agilent is a slow-growing, high-margin lab instrument maker whose headline numbers look steady — revenue $6.95B (+7%), net income $1.30B, gross margin 52.4%, CFFO $1.56B — but two signals from the 18-check screen deserve attention. Accounts receivable grew 12.3% against revenue growth of just 6.7%, and goodwill plus intangibles of $4.9B now equal 73% of stockholders' equity after the $1B BIOVECTRA acquisition. The business itself is solid: a Z-Score of 3.51 places Agilent firmly in the safe zone, the M-Score of -2.46 is below the -2.22 Beneish threshold, and PwC issued a clean opinion after 26 years as the company's auditor. The 10-K also discloses that tariff changes "adversely impacted our costs of revenue beginning in the second half of fiscal year 2025" — the gross margin contraction from 54.3% to 52.4% is already visible.

Business Overview: A Reorganized Three-Segment Lab-Tools Company

Per Item 1 of the 10-K: "Agilent Technologies, Inc. ('we', 'Agilent' or the 'company'), incorporated in Delaware in May 1999, is a global leader in life sciences, diagnostics and applied markets, providing application focused solutions that include instruments, software, services and consumables for the entire laboratory workflow."

The filing discloses a new segment structure: "In November 2024, we announced a change in our organizational structure to support our market-focused, customer-centric strategy... we have three business segments — Life Sciences and Diagnostics Markets, Agilent CrossLab and Applied Markets."

Segment revenue per the MD&A:

The 10-K states that "Revenue from our BIOVECTRA acquisition contributed approximately 2 percentage points in 2025" at the total company level and "approximately 5 percentage points" within the Life Sciences and Diagnostics Markets segment. Organic growth was therefore approximately 5%.

As of October 31, 2025, Agilent employed approximately 18,100 people worldwide, per the filing.

Profitability: Tariffs Compress the Gross Margin

Per the consolidated statements of operations:

The MD&A directly attributes the margin pressure to trade policy: "In the second half of fiscal year 2025, the U.S. government introduced additional measures related to tariffs, including certain increases, exemptions and pauses... While the recent tariff changes adversely impacted our costs of revenue beginning in the second half of fiscal year 2025, we expect to substantially mitigate the impact during our fiscal year 2026."

The 10-K notes net income was "favorably impacted by several tax benefits that reduced our overall tax provision" — in other words, the pre-tax operating picture is weaker than the reported net income growth suggests.

Cash Flow: Still Backs Reported Earnings

Per the consolidated statements of cash flows:

CFFO/NI at 1.20x passes our C1 check — operating cash flow still exceeds reported net income. However, the ratio has been declining for three years (1.43 → 1.36 → 1.20), and absolute CFFO has fallen from $1.77B to $1.56B even as revenue grew. That decline is concurrent with the receivables buildup discussed in the next section.

Free cash flow of $1.15B covers 88% of net income — a pass, but the ratio has slipped from 1.19x two years ago.

The Accounts Receivable Red Flag

This is where our screen flags Agilent. Per the balance sheet:

Our A2 check fails: accounts receivable grew 12.3% against revenue growth of just 6.7%, after AR also grew faster than revenue in 2024 (+2.6% vs -4.7%). Agilent's DSO has climbed by 9 days over two years — from 69 to 78 days. That is the classic early warning the 18-check framework is designed to catch: receivables building faster than the sales they represent.

Two interpretations are consistent with this data:

The MD&A confirms that "Visibility into our markets is limited" and that sales depend on "the capital spending policies of our customers" — pharmaceutical capex has been under pressure. The filing acknowledges 2024 revenue declines "due primarily to the overall pressures on our customers' capital expenditure spending which continued in 2024."

The Goodwill Red Flag: 73% of Equity

Per the balance sheet, following the BIOVECTRA acquisition:

Our D1 check fails: goodwill plus intangibles equal 73% of stockholders' equity, exceeding the 50% threshold. The ratio actually improved from 85% because equity grew while intangibles amortized. The BIOVECTRA acquisition closed September 20, 2024 — Agilent paid approximately $925M for the CDMO business. The 10-K discloses the acquisition was the largest contributor to segment growth in 2025 (+5 percentage points to Life Sciences segment revenue).

This is an elevated-but-not-alarming level for a serial acquirer. Goodwill has been stable (-0.1% YoY) and Agilent's E2 check on goodwill surge passes. There are no impairment charges disclosed. But a single failed CDMO integration could materially impact equity.

Cash and Debt Position: Watch-Level

Per the balance sheet:

Cash of $1.79B covers 53% of total debt of $3.35B — our C4 check flags this as WATCH rather than FAIL (the threshold for fail is typically cash covering less than 33% of debt). Debt/EBITDA of 1.8x is healthy and passes D2. Agilent is not overleveraged. The screening engine flags it only because cash coverage of debt sits below 100%.

The 18-Point Screening

Beneish M-Score Component Breakdown:

The M-Score of -2.46 sits comfortably below the -2.22 Beneish cutoff. Every single component is in a normal range. This is a company with two isolated issues, not a pattern of aggressive accounting.

Altman Z-Score: 3.51 (safe zone). Components: working capital/assets 0.18, retained earnings/assets 0.11, EBIT/assets 0.12, equity/liabilities 1.13. No distress signals.

F-Score: 1.22, fraud probability 0.45%. Very low.

Key Risks from the 10-K (Item 1A)

1. China and Pharmaceutical End-Market Concentration

Per Item 1A: "Demand for some of our products and services depends on the capital spending policies of our customers, research and development budgets and on government funding policies. Our customers include pharmaceutical companies, laboratories, universities, healthcare providers, government agencies and public and private research institutions. Fluctuations in the research and development budgets at these organizations could have a significant effect on the demand for our products and services."

The 2024 revenue decline of -5% and the subdued 2025 organic growth of 5% demonstrate that this is not a theoretical risk. Agilent reported that "our Life Sciences and Diagnostics Markets and Applied Markets segments" declined "mostly in the pharmaceutical market, due primarily to the overall pressures on our customers' capital expenditure spending."

2. International Operations and Tariffs

Per the filing: "Economic, political, foreign currency and other risks associated with international sales and operations could adversely affect our results of operations. Because we sell our products worldwide, our business is subject to risks associated with doing business internationally. We anticipate that revenue from international operations will continue to represent a majority of our total revenue."

The 10-K adds: "Future tariffs and tariffs already implemented could have a negative impact on our business, results of operations and financial condition." The MD&A confirms this is already happening: tariff changes "adversely impacted our costs of revenue beginning in the second half of fiscal year 2025." Gross margin contracted 190 basis points to 52.4%.

3. Customer Visibility Risk

Per Item 1A: "Our quarterly sales and operating results are highly dependent on the volume and timing of orders received during the fiscal quarter, which are difficult to forecast and may be cancelled by our customers." This combined with rising DSO (69 → 78 days over two years) and the AR vs revenue flag suggests Agilent is allowing longer payment terms to maintain order flow.

4. Centralized Accounting in India

An unusual disclosure from Item 1A: "Most of our accounting and tax processes including general accounting, cost accounting, accounts payable, accounts receivable and tax functions are centralized at locations in India." The 10-K warns this creates execution risk that "may be adversely affected and possible delays may occur in reporting financial results." Worth noting given the A2 AR flag and rising DSO.

5. Capital Spending Cycle

Per the filing: "Demand for some of our products and services depends on the capital spending policies of our customers, research and development budgets and on government funding policies." Analytical instruments are capital equipment — the first items to get cut in a pharma budget squeeze.

Auditor's Critical Audit Matter

PricewaterhouseCoopers LLP has served as Agilent's auditor since 1999 — 26 years. The auditor opined: "In our opinion, the consolidated financial statements referred to above present fairly, in all material respects, the financial position of the Company as of October 31, 2025 and 2024, and the results of its operations and its cash flows for each of the three years in the period ended October 31, 2025 in conformity with accounting principles generally accepted in the United States of America."

The Critical Audit Matter is Revenue Recognition for Certain Products and Services: "The principal consideration for our determination that performing procedures relating to revenue recognition for certain products and services and other revenue is a critical audit matter is a high degree of auditor effort in performing procedures related to the Company's revenue recognition."

For Agilent, which sells equipment, consumables, software, and services with multiple performance obligations under a single contract, revenue timing is inherently judgmental. PwC performed "testing revenue recognized for a sample of revenue transactions by obtaining and inspecting source documents, such as purchase orders, invoices, proof of delivery or shipment, and cash receipts." This is standard pharma/life-sciences practice, not a red flag — but it does sit next to our A2 receivables finding.

Key Financial Trends (4-Year)

Summary

Grade: C. Two red flags deserve attention, but the business is fundamentally sound.

Agilent's 18-check screen returned two failures and one watch item. The M-Score of -2.46 is below the manipulation threshold. The Z-Score of 3.51 is comfortably in the safe zone. The F-Score fraud probability is 0.45%. PricewaterhouseCoopers has audited the company for 26 years and issued a clean opinion.

The two failures are:

The 10-K's MD&A also discloses that tariffs already compressed 2025 gross margin by approximately 190 basis points to 52.4%, and management expects to "substantially mitigate the impact during our fiscal year 2026" — an explicit forward-looking commitment worth tracking against Q1 2026 results.

This is not a company with systemic accounting concerns. It is a mature lab-instrument business with two specific data points that warrant investigation rather than dismissal. Read the 10-K. Read the receivables and goodwill footnotes. Then decide.

**Disclaimer**: This report is based on Agilent Technologies' fiscal year 2025 10-K filed with the SEC on December 22, 2025. This is NOT investment advice.

**About EarningsGrade**: We screen earnings reports for financial red flags using an 18-point forensic framework. Grade C means a limited number of specific items warrant investigation.